KRAS G12C MUTANT SOLID TUMORS
Clinical trials for KRAS G12C MUTANT SOLID TUMORS explained in plain language.
Never miss a new study
Get alerted when new KRAS G12C MUTANT SOLID TUMORS trials appear
Sign up with your email to follow new studies for KRAS G12C MUTANT SOLID TUMORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo targets tough cancers with KRAS mutation
Disease control OngoingThis study tests a drug called JDQ443, alone or with other treatments, in people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to see if the drug is safe and can shrink tumors. About 344 adults with lung, colorectal, or other cancers who have tri…
Matched conditions: KRAS G12C MUTANT SOLID TUMORS
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 07:35 UTC
-
New combo therapy targets Hard-to-Treat cancers with KRAS mutation
Disease control OngoingThis study is for people with advanced solid tumors (like lung or colorectal cancer) that have a specific genetic change called KRAS G12C. It tests a new drug, JDQ443, combined with other treatments to see if they are safe and can shrink tumors. About 74 adults will take part. Th…
Matched conditions: KRAS G12C MUTANT SOLID TUMORS
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 19, 2026 11:59 UTC